glp-1 agonist drugs oral The Impact of Receptor Agonists on Sedation Every GLP-1 Agonist Drug You
Description
Data were pooled for glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl-peptidase 4 (DPP-4) inhibitors in comparison with their respective controls and expressed as exposure-adjusted incidence rates
Clinical studies have shown that, on average, patients may lose up to 1015% of their body weight within the first 6 months
As the mechanisms underlying disease pathology are unveiled, various therapeutics are being repurposed for their use in neuro-ophthalmology
Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs)
However, considering the mechanism of this drug class, questions remain regarding the carcinogenic potential
Funding The author(s) declared that financial support was not received for this work and/or its publication
